Moreover, an OS benefit with the combination treatment was noted among subgroups of patients with special characteristics, including those with sarcomatoid features, history of nephrectomy, and liver, bone, or lung metastases at baseline.

The patient was admitted to the hospital for fever and symptomatic bone metastases pain that was unresponsive to ceftriaxone administered in the outpatient setting.

The cohort of 803 English patients aged 12–24 years at time of diagnosis included 155 patients with germ cell and trophoblastic neoplasms, 77% of whom had testicular cancer, as well as patients with leukemia, lymphoma, carcinoma, central nervous system or bone tumors and soft tissue sarcoma.

Adding regional hyperthermia to neoadjuvant chemotherapy significantly improves survival in patients with localized high-risk soft tissue sarcoma, researchers report.

Immunotherapy could have a role in the treatment of patients with certain sarcoma subtypes in the advanced disease setting, suggests research presented at the 2017 annual meeting of the American Society of Clinical Oncology. Here we provide a round-up of three studies investigating various immunotherapeutic strategies in advanced sarcoma patients.

The doxorubicin conjugate aldoxorubicin could be a suitable alternative to standard therapies for patients with relapsed or refractory soft tissue sarcoma, say researchers.

Furthermore, it remains to be confirmed whether CAR T cells migrate towards, and penetrate into lymph nodes as efficiently as they do bone marrow.